US FDA approves Scholar Rock drug for rare muscle-wasting disease
The U.S. Food and Drug Administration approved Scholar Rock's NASDAQ:SRRK therapy on Friday to treat a rare genetic condition that causes muscle weakness.The therapy, sold as Isembyld, is the first muscle-targeted therapy designed to improve motor function for adults and children with spinal muscul…